M-CSF treatment does not compromise HSC self-renewal, multilineage differentiation, or stem cell activity. (a) Mice were transplanted with actin-GFP HS/PCs and treated with rmM-CSF, rhG-CSF, or PBS as described in Fig. 1 a and analyzed after 17 wk for donor cell contribution in blood and bone marrow. (b and c) Percentage of GFP⁺ donor cell contribution to CD11b⁺ myeloid, CD19⁺ B cells, or CD3e⁺ T cells in blood of reconstituted mice (b) or expressed as a ratio of CD11b⁺ myeloid cells to CD19⁺ lymphoid cells (c). (d) Percentage of GFP⁺ donor cell contribution and percentage of total bone marrow cells for c-kit⁺ progenitors and HS/PCs (KSL). (e) Percentage of GFP⁺ donor cell contribution to indicated stem and progenitor cell populations. (f) Percentage of GFP⁺ donor cell contribution to myeloid and lymphoid cells in blood 7 wk after secondary transplantation. Error bars represent the median with range. *, P < 0.05; **, P < 0.01 by Mann-Whitney U tests. All data are representative of two independent experiments.